Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
VGX-001-013 (EMERGE) is a Phase 2b study to evaluate an investigational new drug, mizagliflozin, for safety, tolerability and its ability to prevent low blood sugar in patients with post-bariatric hypoglycemia.
Epistemonikos ID: 111da1023ee730e2b8837bae41817363baf06bcb
First added on: Aug 12, 2026